SMT202100166T1 - Derivati di 2, 2-difluoropropionammide di bardoxolone metile, composizioni farmaceutiche e loro polimorfi per l'uso nel trattamento di determinate condizioni - Google Patents

Derivati di 2, 2-difluoropropionammide di bardoxolone metile, composizioni farmaceutiche e loro polimorfi per l'uso nel trattamento di determinate condizioni

Info

Publication number
SMT202100166T1
SMT202100166T1 SM20210166T SMT202100166T SMT202100166T1 SM T202100166 T1 SMT202100166 T1 SM T202100166T1 SM 20210166 T SM20210166 T SM 20210166T SM T202100166 T SMT202100166 T SM T202100166T SM T202100166 T1 SMT202100166 T1 SM T202100166T1
Authority
SM
San Marino
Prior art keywords
difluoropropionamide
polymorphs
derivative
pharmaceutical compositions
certain conditions
Prior art date
Application number
SM20210166T
Other languages
English (en)
Italian (it)
Inventor
Eric Anderson
Andrea Decker
Xiaofeng Liu
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of SMT202100166T1 publication Critical patent/SMT202100166T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/45Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
SM20210166T 2012-04-27 2013-04-24 Derivati di 2, 2-difluoropropionammide di bardoxolone metile, composizioni farmaceutiche e loro polimorfi per l'uso nel trattamento di determinate condizioni SMT202100166T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261687669P 2012-04-27 2012-04-27
US201361775288P 2013-03-08 2013-03-08
US201361780444P 2013-03-13 2013-03-13
EP17175885.7A EP3444261B1 (en) 2012-04-27 2013-04-24 2,2-difluoropropionamide derivative of bardoxolone methyl, pharmaceutical compositions and polymorphs thereof for use in treating certain conditions

Publications (1)

Publication Number Publication Date
SMT202100166T1 true SMT202100166T1 (it) 2021-05-07

Family

ID=49483867

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20170396T SMT201700396T1 (it) 2012-04-27 2013-04-24 Derivati di 2,2-difluoropropionammide di bardoxolone metile, loro forme polimorfiche e metodi d'uso
SM20210166T SMT202100166T1 (it) 2012-04-27 2013-04-24 Derivati di 2, 2-difluoropropionammide di bardoxolone metile, composizioni farmaceutiche e loro polimorfi per l'uso nel trattamento di determinate condizioni

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20170396T SMT201700396T1 (it) 2012-04-27 2013-04-24 Derivati di 2,2-difluoropropionammide di bardoxolone metile, loro forme polimorfiche e metodi d'uso

Country Status (40)

Country Link
US (5) US8993640B2 (enExample)
EP (2) EP3444261B1 (enExample)
JP (2) JP6410710B2 (enExample)
KR (1) KR102101774B1 (enExample)
CN (1) CN104395332B (enExample)
AR (1) AR092823A1 (enExample)
AU (1) AU2013251602B2 (enExample)
BR (1) BR112014026640B1 (enExample)
CA (1) CA2869783C (enExample)
CL (1) CL2014002886A1 (enExample)
CO (1) CO7170182A2 (enExample)
CY (3) CY1119333T1 (enExample)
DK (2) DK2841445T3 (enExample)
DO (1) DOP2014000236A (enExample)
EA (1) EA030468B1 (enExample)
ES (2) ES2634315T3 (enExample)
FI (1) FIC20240012I1 (enExample)
FR (1) FR24C1015I2 (enExample)
HK (1) HK1207085A1 (enExample)
HR (1) HRP20171275T1 (enExample)
HU (3) HUE053113T2 (enExample)
IL (1) IL235275B (enExample)
LT (3) LT2841445T (enExample)
ME (1) ME02926B (enExample)
MX (2) MX357060B (enExample)
MY (1) MY172750A (enExample)
NL (1) NL301276I2 (enExample)
NZ (1) NZ630222A (enExample)
PE (1) PE20150160A1 (enExample)
PL (2) PL3444261T3 (enExample)
PT (2) PT3444261T (enExample)
RS (2) RS61544B1 (enExample)
SG (1) SG11201406868XA (enExample)
SI (2) SI2841445T1 (enExample)
SM (2) SMT201700396T1 (enExample)
TW (2) TWI623548B (enExample)
UA (1) UA116209C2 (enExample)
UY (1) UY34764A (enExample)
WO (1) WO2013163344A1 (enExample)
ZA (1) ZA201407326B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
ME02973B (me) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
LT2841445T (lt) 2012-04-27 2017-09-11 Reata Pharmaceuticals, Inc. Bardoksolonmetilo 2,2-difluorpropionamido dariniai, polimorfinės formos ir jų panaudojimo būdai
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PT2892912T (pt) 2012-09-10 2019-07-12 Reata Pharmaceuticals Inc Derivados c17-alcanodiilo e alcenodiilo de ácido oleanólico e métodos de utilização dos mesmos
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
US20170333450A1 (en) 2014-10-31 2017-11-23 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
CN112384807A (zh) 2018-05-24 2021-02-19 雷尼布斯治疗公司 治疗有风险患有肾损伤和肾衰竭的患者的方法
IL322405A (en) 2018-06-15 2025-09-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
ES2974026T3 (es) 2018-08-20 2024-06-25 Janssen Pharmaceutica Nv Inhibidores de la interacción proteína-proteína entre KEAP1-Nrf2
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
WO2020167969A1 (en) * 2019-02-15 2020-08-20 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
JP7695229B2 (ja) 2019-07-19 2025-06-18 リアタ ファーマシューティカルズ インコーポレイテッド C17極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法
WO2021113551A1 (en) * 2019-12-03 2021-06-10 Baylor College Of Medicine Therapeutic compounds for methods of use in insulin resistance
CN115052584B (zh) 2020-01-24 2024-08-23 特维迪疗法公司 治疗性化合物及其制剂和用途
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
WO2022155614A1 (en) 2021-01-18 2022-07-21 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) * 2021-06-23 2022-07-01 华中农业大学 一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
CN117050134A (zh) * 2022-05-05 2023-11-14 中国科学院上海有机化学研究所 酰胺化合物的合成及其用途
IL317006A (en) 2022-06-15 2025-01-01 Tvardi Therapeutics Inc Prodrugs of 3STAT inhibitors
CN115165838B (zh) * 2022-06-23 2025-09-30 中国医学科学院血液病医院(中国医学科学院血液学研究所) 基于拉曼光谱和血清代谢构建mds和aml鉴别模型的方法和试剂盒
US20240124393A1 (en) 2022-09-21 2024-04-18 Sicor - Societa Italiana Corticosteroidi S.R.L. Process and intermediates for preparation of omaveloxolone and salts thereof
WO2025029691A1 (en) * 2023-07-28 2025-02-06 Reata Pharmaceuticals Holdings, LLC Methods for producing triterpenoid derivatives
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5555153Y2 (enExample) 1975-03-19 1980-12-20
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
NZ515675A (en) 1999-05-14 2004-06-25 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
WO2002026761A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
EP1395255A4 (en) 2000-11-28 2007-09-12 Univ Texas CDDO COMPOUNDS AND ASSOCIATED POLYTHERAPIES
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2002092768A2 (en) 2001-05-14 2002-11-21 University Of Maryland, Baltimore Novel alanine transaminase enzyme and methods of use
AU2003235676A1 (en) 2002-01-15 2003-07-30 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP2005519913A (ja) 2002-01-18 2005-07-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 生物学的に活性な表面活性剤としてのトリテルペン第4アンモニウム塩
WO2004064723A2 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
WO2006029221A2 (en) 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
US8288439B2 (en) 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
JP2009530405A (ja) 2006-03-23 2009-08-27 アドバンスト ライフ サイエンシズ インコーポレイテッド 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
WO2008000068A1 (en) 2006-06-27 2008-01-03 Wellington Laboratories Inc. Method for preparing 2-iodo triterpenoid compounds
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008016095A1 (en) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
CA2670099A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2680009A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009058849A1 (en) 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
ME03529B (me) 2008-01-11 2020-04-20 Reata Pharmaceuticals Inc Sintetički triterpenoidi i metode njihove upotrebe u tretmanu bolesti
CN102066398B (zh) 2008-04-18 2014-09-10 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
MX2010011437A (es) 2008-04-18 2010-12-20 Reata Pharmaceuticals Inc Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c.
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
JP5529851B2 (ja) 2008-04-18 2014-06-25 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター:c−17においてアミノ改変およびその他の改変を加えたオレアノール酸誘導体
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
EP2362770A4 (en) 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
JP5775464B2 (ja) 2009-02-13 2015-09-09 リアタ ファーマシューティカルズ,インク 非晶質cddo−meを含有する遅延放出性経口投薬組成物
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
ES2768204T3 (es) 2010-04-12 2020-06-22 Reata Pharmaceuticals Inc Metil bardoxolona para el tratamiento de la obesidad
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
ME02973B (me) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
MA34909B1 (fr) 2011-01-31 2014-02-01 Bristol Myers Squibb Co Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
CN102153613B (zh) 2011-02-28 2013-08-14 贵州省中国科学院天然产物化学重点实验室 夏枯草酸的制备方法和应用
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
LT2841445T (lt) 2012-04-27 2017-09-11 Reata Pharmaceuticals, Inc. Bardoksolonmetilo 2,2-difluorpropionamido dariniai, polimorfinės formos ir jų panaudojimo būdai
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru) 2012-07-13 2013-07-20 Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CA2884400A1 (en) 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
NZ705213A (en) 2012-09-10 2018-07-27 Reata Pharmaceuticals Inc C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
PT2892912T (pt) 2012-09-10 2019-07-12 Reata Pharmaceuticals Inc Derivados c17-alcanodiilo e alcenodiilo de ácido oleanólico e métodos de utilização dos mesmos
WO2014048033A1 (en) 2012-09-28 2014-04-03 Applied Pharmaceutical Science, Inc. Polymorphs of cddo ethyl ester and uses thereof
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
MX380589B (es) 2013-08-23 2025-03-12 Reata Pharmaceuticals Holdings Llc Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxolona o sus análogos.
EP3097089B1 (en) 2014-01-24 2021-02-24 Reata Pharmaceuticals, Inc. Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物

Also Published As

Publication number Publication date
US12065464B2 (en) 2024-08-20
MX387999B (es) 2025-03-19
TWI623548B (zh) 2018-05-11
CY2024012I2 (el) 2024-12-13
UY34764A (es) 2013-11-29
DK2841445T3 (en) 2017-09-11
CL2014002886A1 (es) 2015-02-06
KR20150003875A (ko) 2015-01-09
SI2841445T1 (sl) 2017-12-29
US20210355156A1 (en) 2021-11-18
CY1124130T1 (el) 2022-05-27
ZA201407326B (en) 2016-10-26
LT3444261T (lt) 2021-05-10
SI3444261T1 (sl) 2021-04-30
US9701709B2 (en) 2017-07-11
UA116209C2 (uk) 2018-02-26
AU2013251602A1 (en) 2014-10-23
US20150259377A1 (en) 2015-09-17
TW201348245A (zh) 2013-12-01
HUE053113T2 (hu) 2021-06-28
CN104395332B (zh) 2017-01-18
NZ630222A (en) 2016-06-24
DOP2014000236A (es) 2015-04-30
IL235275B (en) 2018-03-29
LTC2841445I2 (enExample) 2025-10-10
CA2869783C (en) 2022-06-21
SMT201700396T1 (it) 2017-09-07
JP6637136B2 (ja) 2020-01-29
DK3444261T3 (da) 2021-03-08
HRP20171275T1 (hr) 2017-10-20
MX357060B (es) 2018-06-25
CA2869783A1 (en) 2013-10-31
ES2861393T3 (es) 2021-10-06
FR24C1015I1 (fr) 2024-06-28
PL2841445T3 (pl) 2017-10-31
CN104395332A (zh) 2015-03-04
MY172750A (en) 2019-12-11
EP2841445B1 (en) 2017-06-14
BR112014026640A2 (pt) 2017-07-18
LT2841445T (lt) 2017-09-11
NL301276I2 (nl) 2024-06-24
TW201726701A (zh) 2017-08-01
US20180009839A1 (en) 2018-01-11
US11078230B2 (en) 2021-08-03
RS61544B1 (sr) 2021-04-29
PL3444261T3 (pl) 2021-07-19
PE20150160A1 (es) 2015-02-19
LTPA2024511I1 (enExample) 2024-05-10
EP2841445A1 (en) 2015-03-04
HUE035673T2 (en) 2018-05-28
PT3444261T (pt) 2021-03-12
HK1207086A1 (en) 2016-01-22
AR092823A1 (es) 2015-05-06
EA030468B1 (ru) 2018-08-31
PT2841445T (pt) 2017-09-01
WO2013163344A1 (en) 2013-10-31
SG11201406868XA (en) 2014-11-27
MX2014013076A (es) 2015-05-11
CO7170182A2 (es) 2015-01-28
US20130324599A1 (en) 2013-12-05
HK1207085A1 (en) 2016-01-22
JP2015521166A (ja) 2015-07-27
EP3444261B1 (en) 2021-01-13
BR112014026640B1 (pt) 2021-05-18
ES2634315T3 (es) 2017-09-27
EA201491972A1 (ru) 2015-02-27
HUS2400010I1 (hu) 2024-05-28
US20250051388A1 (en) 2025-02-13
FR24C1015I2 (fr) 2025-05-02
AU2013251602B2 (en) 2017-09-28
CY2024012I1 (el) 2024-12-13
US8993640B2 (en) 2015-03-31
ME02926B (me) 2018-04-20
JP6410710B2 (ja) 2018-10-24
FIC20240012I1 (fi) 2024-04-18
JP2019011349A (ja) 2019-01-24
KR102101774B1 (ko) 2020-04-20
CY1119333T1 (el) 2018-02-14
EP3444261A1 (en) 2019-02-20
RS56154B1 (sr) 2017-11-30

Similar Documents

Publication Publication Date Title
PT3444261T (pt) Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
IL268984B (en) Derivatives of oxyntomodulin and a pharmaceutical preparation containing them for the treatment of obesity
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
ZA201406145B (en) Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
PL2877168T3 (pl) Farmaceutyczna lub kosmetyczna kompozycja do leczenia łysienia
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
PT2940014T (pt) Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo
DK3292875T3 (en) Compositions and methods for treating diseases
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
ZA201403431B (en) Pharmaceutical compositions and methods of use of 4-pregenen-11b-21-triol-3,20-dione derivatives
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
ZA201309559B (en) Comptothecin derivative, method for preparing same, pharmaceutical composition and use thereof
ZA201307216B (en) Novel oxazolidinone derivative and pharmaceutical composition including the same
IL254289A0 (en) History of fatty acids and pharmaceutical preparations containing them for the treatment of schizophrenia
EP2930175A4 (en) NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USES THEREFOR, AND THE DERIVATIVE THEREOF
EP2785342A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERTRIGLYCERIDEMIA OR DISEASES ASSOCIATED WITH HYPERTRIGLYCERIDEMIA
PT3539540T (pt) Inibidor de sglt2 1-cloro-4-(beta-d-glucopiranos-1-il)-2-[4-((s)-tetra-hidrofurano-3-iloxi)-benzil]-benzeno em combinação com insulina para utilização num método para redução do risco de hipoglicemia